What is Revance Therapeutics Forward Dividend Yield %?
As of today (2024-04-29), the Forward Annual Dividend Yield of Revance Therapeutics is 0.00%.
As of today (2024-04-29), the Trailing Annual Dividend Yield of Revance Therapeutics is 0.00%.
RVNC's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.56 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Revance Therapeutics's Forward Dividend Yield %
For the Biotechnology subindustry, Revance Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revance Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Revance Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Revance Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Revance Therapeutics (Revance Therapeutics) Business Description
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVNC has been successfully added to your